AI medical scribes
26 – 33Suki by 7
| Dimension | DeepScribe | Suki | Gap |
|---|---|---|---|
| Workflow & templatesTemplate depth and per-clinician customization, breadth of note types and specialties, non-physician coverage, and whether the tool can work on a note it did not draft. | 5 | 7 | -2 |
| EHR & deploymentIntegration depth — native embed, authenticated API write-back, browser extension or copy-paste — plus enterprise rollout support and the procurement path. | 7 | 9 | -2 |
| Clinical reasoningWhether the product reasons about the encounter or only records it: ranked differential, problem-based assessment and plan, red-flag detection, and whether that reasoning is auditable rather than opaque. | 4 | 5 | -1 |
| Documentation integrityICD-10 specificity, MEAT support, HCC recapture, E/M leveling and denial-risk checks — and whether each suggestion traces to verbatim text in the note so it survives an audit. | 7 | 8 | -1 |
| Access & pricePublished pricing, free tier, credential and regional eligibility, language coverage, and whether one clinician can evaluate the product without entering a sales process. | 3 | 4 | -1 |
DeepScribe
- Best for
- Community oncology practices on OncoEMR or iKnowMed, where the documentation problem is capturing MEAT criteria against HCC conditions. It is the only tool scored here that documents a per-condition Monitor, Evaluate, Assess and Treat summary.
- Limitation
- Almost nothing is publicly checkable: no price, no template, note-type or specialty count, no developer API and no product documentation site at all. Its widely-quoted 98.8 KLAS score is an Emerging Company Spotlight carrying the vendor's own limited-data asterisk, and the same vendor quotes it as 98.3 elsewhere.
- Price
- Not published; enterprise, sales-led
Suki
- Best for
- Health systems on Epic, Oracle Health, athenahealth or MEDITECH that need HCC-aware coding written straight into EHR fields rather than parked in a tab, plus the best-documented multilingual capture in the category at 80+ languages with published language IDs.
- Limitation
- No published price, no trial and no self-serve path, so an individual clinician cannot evaluate it at all. KLAS's own listing marks it limited market share on 18 organisations — too few live customers to qualify for the ranking Abridge has won twice — against Suki's claim of 400+ systems and partners.
- Price
- Not published; sales-led. The pricing page returns a 404.
